<SEC-DOCUMENT>0001628280-26-015458.txt : 20260306
<SEC-HEADER>0001628280-26-015458.hdr.sgml : 20260306
<ACCEPTANCE-DATETIME>20260306080742
ACCESSION NUMBER:		0001628280-26-015458
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20260306
FILED AS OF DATE:		20260306
DATE AS OF CHANGE:		20260306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prenetics Global Ltd
		CENTRAL INDEX KEY:			0001876431
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41401
		FILM NUMBER:		26728511

	BUSINESS ADDRESS:	
		STREET 1:		7/F, K11 ATELIER, 728 KING'S ROAD
		CITY:			QUARRY BAY
		STATE:			K3
		ZIP:			000000
		BUSINESS PHONE:		(852) 2210-7188

	MAIL ADDRESS:	
		STREET 1:		7/F, K11 ATELIER, 728 KING'S ROAD
		CITY:			QUARRY BAY
		STATE:			K3
		ZIP:			000000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a6-k060326sharebuybackprog.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i7b155231dd134eb4a7e87c4f3d05710d_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8.75pt;padding-right:8.75pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:100%">UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Washington, D.C. 20549</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:100%">Form&#160;6-K</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE<br>13a-16 OR 15d-16 UNDER<br>THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">For the month of March 2026</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Commission File Number 001-41401 </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:100%">Prenetics Global Limited</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.743%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Unit 703-706, K11 Atelier</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">728 King&#8217;s Road, Quarry Bay </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Hong Kong</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Addresses of principal executive offices)</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&#160;20-F or Form&#160;40-F.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Form 20-F&#8194;&#9746;&#8195;Form 40-F&#8194;&#9744;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8.75pt;padding-right:8.75pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">EXPLANATORY NOTE</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">On March 6, 2026, Prenetics Global Limited (the &#8220;Company&#8221;) issued a press release announcing that its Board of Directors authorized a share repurchase program of up to $40 million of its Class A Ordinary Shares. A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT INDEX</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.711%"><tr><td style="width:1.0%"></td><td style="width:12.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit no. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="pre_sharerepurchasexpressr.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Press Release - Prenetics Authorizes $40 Million Share Repurchase Program</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">SIGNATURES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Prenetics Global Limited</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lo Hoi Chun</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lo Hoi Chun</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 6, 2026</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pre_sharerepurchasexpressr.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i365b3f4ee5974fe9bb3984a18c766a07_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:center"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Prenetics Authorizes $40 Million Share Repurchase Program</font></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:center"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management and Board Have Collectively Committed Up to $42.75 Million to Prenetics Stock  </font></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:center"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Backed by $164 Million in Total Adjusted Liquidity, Zero Debt </font></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:center"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IM8 Targeting $180M to $200M in 2026 Full Year Revenue, and a Clear Path to Adjusted EBITDA Profitability by Q4 2027</font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEW YORK, N.Y., March 6, 2026 (GLOBE NEWSWIRE) </font><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Prenetics Global Limited (NASDAQ&#58; PRE) (&#34;Prenetics&#34; or the &#34;Company&#34;), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced that its Board of Directors (the &#8220;Board&#8221;) has authorized a share repurchase program of up to $40,000,000 over a 12-month period.</font></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><font><br></font></div><div style="margin-bottom:4pt;margin-top:10pt"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management Voted With Its Own Capital First</font></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the week of February 23 to 27, 2026, members of the Prenetics executive leadership team made open market purchases totaling approximately $1.3 million at an average price of approximately $17.11 per share. CEO Danny Yeung personally purchased approximately $750,000 in that round alone.</font></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Combined with approximately $1.45 million in purchases following the prior earnings release in November 2025, Prenetics&#8217; executive team has now invested a cumulative $2.75 million of personal capital into the Company&#8217;s stock across two consecutive post-earnings open trading windows.</font></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board&#8217;s authorization of a $40 million corporate share repurchase program is the institutional expression of the same conviction. Together, that is up to $42.75 million committed to Prenetics stock by the people who know this business best.</font></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Danny Yeung, CEO of Prenetics, commented&#58; &#8220;</font><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have spent the past year doing exactly what we said we would do &#8212; building IM8 into one of the fastest-growing supplement brands in the world, strengthening our balance sheet, and eliminating complexity. Our $40 million share repurchase program is the natural next step&#58; a direct expression of the Board's view that the current share price does not yet reflect the underlying value and trajectory of this business. With approximately $164 million in total adjusted liquidity, zero debt, and IM8 on a trajectory toward $180 million to $200 million in 2026 revenue, we have more than sufficient capital to fund growth and this buyback through to profitability &#8212; which we are targeting at adjusted EBITDA level by Q4 2027 on the strength of IM8's unit economics. Our executive team has already invested approximately $2.75 million of personal capital in Prenetics stock across recent post-earnings trading windows. This share repurchase program reinforces that same conviction at the institutional level. When you have the capital, the runway, and the business momentum &#8212; buying back your own stock is simply the right thing to do for shareholders. That leaves a straightforward decision&#58; hold excess cash at negligible real yield, reinvest it into a business already funded through its profitability horizon, or return it to shareholders by buying stock that management believes is materially undervalued. The Board chose the third option. At current prices, Prenetics trades at an enterprise value of approximately $89 million &#8212; less than 0.5x IM8's 2026 revenue guidance of $180 million to $200 million. Stripping out the Company's approximately $164 million in total adjusted liquidity, the market is effectively ascribing near-zero value to a business targeting $180 million to 200 million in revenue this year and adjusted EBITDA profitability by Q4 2027.</font><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font></div><div style="margin-bottom:4pt;margin-top:10pt"><font><br></font></div><div style="margin-bottom:4pt;margin-top:10pt"><font><br></font></div><div style="margin-bottom:4pt;margin-top:10pt"><font><br></font></div><div style="margin-bottom:4pt;margin-top:10pt"><font><br></font></div><div style="margin-bottom:4pt;margin-top:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:4pt;margin-top:10pt"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Strength Underpins the Program</font></div><div style="margin-bottom:5pt;margin-top:4pt"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2025 and into early 2026, Prenetics completed three strategic divestitures &#8212; each designed to concentrate the Company's capital and operating focus on its highest-growth, highest-margin business in IM8&#58;</font></div><div style="margin-top:4pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1a2b5c;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">DIVESTITURE</font></td><td colspan="3" style="background-color:#1a2b5c;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PROCEEDS</font></td><td colspan="3" style="background-color:#1a2b5c;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">BUYER</font></td></tr><tr><td colspan="3" style="background-color:#f4f6fa;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#1a2b5c;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ACT Genomics</font></td><td colspan="3" style="background-color:#f4f6fa;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#1c1c1c;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to &#126;$72M cash (&#126;$46M gross to Company)</font></td><td colspan="3" style="background-color:#f4f6fa;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#1c1c1c;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delta Electronics</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#1a2b5c;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Europa Distribution Business</font></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#1c1c1c;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to $13M (all-stock consideration)</font></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#1c1c1c;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategic acquirer</font></td></tr><tr><td colspan="3" style="background-color:#f4f6fa;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#1a2b5c;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35% equity stake in Insighta</font></td><td colspan="3" style="background-color:#f4f6fa;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#1c1c1c;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$70M cash</font></td><td colspan="3" style="background-color:#f4f6fa;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#1c1c1c;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tencent</font></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:4pt"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The result&#58; total adjusted liquidity</font><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of approximately $164 million as of March 1, 2026, on a zero-debt basis.</font></div><div style="margin-bottom:5pt;margin-top:4pt"><font><br></font></div><div style="margin-bottom:4pt;margin-top:10pt"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Capital Allocation Case</font></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With approximately $164 million in total adjusted liquidity and zero debt as of March 1, 2026, Prenetics is not running a capital return program because it has run out of better options. It is running one because the numbers make it the most disciplined choice available.</font></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IM8&#8217;s unit economics are strong and improving. The business is on a clear path to profitability, with the Company targeting break-even and sustained profitability in adjusted EBITDA terms by Q4 2027. The Company has more than sufficient capital to fund IM8&#8217;s growth through profitability trajectory without deploying the full liquidity on its balance sheet today.</font></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">That leaves a straightforward decision&#58; hold excess cash at negligible real yield, reinvest it into a business already funded through its profitability horizon, or return it to shareholders by buying stock that management believes is materially undervalued. The Board chose the third option.</font></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><font><br></font></div><div style="margin-bottom:4pt;margin-top:10pt"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Asset the Board Is Buying&#58; IM8</font></div><div><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prenetics has spent three years making hard choices &#8212; divesting, simplifying, concentrating. Every decision pointed to the same destination&#58; IM8. Co-founded with David Beckham, championed by World No. 1 tennis player Aryna Sabalenka and F1 phenom Ollie Bearman, IM8 is built on NSF Certified for Sport, clinically validated nutrition &#8212; and it is the business the Board is backing with up to $40 million.</font></div><div><font><br></font></div><div style="margin-bottom:4pt;margin-top:10pt"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Program Structure</font></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board also authorized the Company to enter into written trading plans under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Under any Rule 10b5-1 trading plan, the Company&#8217;s third-party broker, subject to Securities and Exchange Commission regulations regarding certain price, market, volume and timing constraints, would have authority to purchase the Company&#8217;s Class A Ordinary Shares in accordance with the terms of the plan. Under the share repurchase program, the Company is authorized to repurchase its outstanding Class A Ordinary Shares through open market purchases, </font></div><div style="border-bottom:0.45pt solid #1a1a1a;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Adjusted liquidity is a non-IFRS financial measure, comprising&#58; cash and cash equivalents of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$93.0 million</font><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, financial assets at fair value through profit or loss (primarily comprising of fixed income funds) of approximately </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$29.3 million</font><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> based on the most recent available valuation and subject to finalization as part of the ongoing annual audit, digital asset holdings valued at approximately </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$34.2 million</font><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and portions of gross proceeds of the ACT Genomics sale and Insighta sale transactions held in escrow pending fulfillment of customary release conditions of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$6.3 million</font><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$1.0 million</font><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, respectively. Our total adjusted liquidity decreased from approximately $171 million as of February 15, 2026 to approximately $164 million as of March 1, 2026 on account of expenses used to support inventory growth and marketing costs on advertising services.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">privately negotiated transactions, block purchases, or otherwise in accordance with applicable U.S. federal securities laws. The Company cannot predict when, or if, it will repurchase any Class A Ordinary Shares as such share repurchase program will depend on a number of factors, including constraints specified in any Rule 10b5-1 trading plan, price, general business and market conditions, and alternative investment opportunities. The share repurchase program may be modified, suspended or discontinued at any time without prior notice. The share repurchase program does not obligate the Company to acquire any specific number or dollar amount of shares and may be suspended or discontinued at any time.</font></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><font><br></font></div><div style="margin-bottom:4pt;margin-top:10pt"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Prenetics</font></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prenetics (NASDAQ&#58; PRE) is a leading health sciences company dedicated to advancing human health and longevity. The Company&#8217;s flagship consumer brand, IM8, co-founded with David Beckham and championed by World No. 1 tennis player Aryna Sabalenka, is redefining the premium daily nutrition category through science-backed formulations and global brand partnerships. Since its launch, IM8 has become one of the fastest-growing brands in consumer health, achieving an impressive milestone of surpassing $100 million in annualized recurring revenue within just 11 months of operations, and is now sold in more than 30 countries worldwide.</font></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><font><br></font></div><div style="margin-bottom:4pt;margin-top:10pt"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About IM8</font></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature&#8217;s most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8&#8217;s flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ&#58; PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit www.IM8health.com.</font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-bottom:4pt;margin-top:10pt"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Relations Contact&#58;</font></div><div style="margin-bottom:4pt;margin-top:4pt"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investors&#64;prenetics.com</font></div><div style="margin-bottom:4pt;margin-top:4pt"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRE&#64;mzgroup.us</font></div><div style="margin-bottom:4pt;margin-top:4pt"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Angela Cheung</font></div><div style="margin-bottom:4pt;margin-top:4pt"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investor Relations &#47; Corporate Finance</font></div><div style="margin-bottom:4pt;margin-top:4pt"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">angela.hm.cheung&#64;prenetics.com</font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-bottom:4pt;margin-top:10pt"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains forward-looking statements. These statements are made under the &#8220;safe harbor&#8221; provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company&#8217;s goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. Our guidance reflects management&#8217;s current estimates and assumptions as of the date of this release, is subject to significant risks and uncertainties, and is not a guarantee of future performance. Actual results may differ materially. In some cases, forward-looking statements can be identified by words or phrases such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;target,&#8221; &#8220;aim,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;is&#47;are likely to,&#8221; &#8220;guidance,&#8221; &#8220;outlook,&#8221; &#8220;forecast,&#8221; or other similar expressions. Forward-looking statements are based upon estimates and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><font style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, and therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to&#58; future alpha-generating activities involving the Company&#8217;s digital asset holdings could expose it to additional risks&#59; the Company&#8217;s purchase of digital asset subjects it to risks related to extreme volatility and speculative nature of digital asset&#59; the Company may not be able to maintain and enhance its IM8 business and brand if it suffers negative publicity or fails to maintain a strong base of engaged customers and content creators, or otherwise fails to meet customers&#8217; expectations&#59; the Company&#8217;s ability to further develop and grow its business, including new products and services&#59; and its ability to identify and execute on M&#38;A opportunities. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the &#8220;Risk Factors&#8221; section of the Company&#8217;s most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. Unless otherwise specified, all information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
